✦ LIBER ✦

A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis

✍ Scribed by F. Ratjen; R. Wönne; H.-G. Posselt; B. Stöver; D. Hofmann; S. W. Bender

Publisher: Springer
Year: 1985
Tongue: English
Weight: 497 KB
Volume: 144
Category: Article
ISSN: 0340-6997
DOI: 10.1007/bf00441781

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

French multicenter randomized double-bli

French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients

✍ Gérard Pons; M.C. Marchand; P. d'Athis; E. Sauvage; C. Foucard; P. Chaumet-Riffa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB 👁 2 views

Oral type II collagen treatment in early

Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial

✍ Joachim Sieper; Sonja Kary; Helmut Sörensen; Rieke Alten; Ulrich Eggens; Werner 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 951 KB

Placebo-controlled, double-blind, random

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

✍ Heinz Georg Wiesemann; Gratiana Steinkamp; Felix Ratjen; Adolf Bauernfeind; Barb 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 2 views

In chronic Pseudomonas aeruginosa pulmonary infection of patients with cystic fibrosis (CF), antibiotic therapy generally fails to eradicate the bacterial pathogen. The mucoid bacterial phenotype, high sputum production by the host, and low airway levels of antibiotics seem to be responsible for the

Treatment of rheumatoid arthritis with o

Treatment of rheumatoid arthritis with oral type II collagen: Results of a multicenter, double-blind, placebo-controlled trial

✍ Martha L. Barnett; Joel M. Kremer; E. William St. Clair; Daniel O. Clegg; Daniel 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 892 KB

Sarizotan as a treatment for dyskinesias

Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial

✍ Christopher G. Goetz; Philippe Damier; Christine Hicking; Eugene Laska; Thomas M 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract The objective of this study is to conduct a dose‐finding study of sarizotan in Parkinson's disease (PD) patients with dyskinesia to identify a safe dose and to identify a sensitive dyskinesia rating measure. Sarizotan is a novel compound with full 5‐HT~1A~ agonist properties and additio

Ursodeoxycholic acid for liver disease a

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: A double-blind multicenter trial

✍ C Colombo; P M Battezzati; M Podda; N Bettinardi; A Giunta 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 204 KB 👁 1 views

AND THE ITALIAN GROUP FOR THE STUDY OF URSODEOXYCHOLIC ACID IN CYSTIC FIBROSIS\* ment. Thus, we concluded that UDCA administration im-Liver disease is increasingly recognized as a major proves clinical and biochemical parameters in CF pacause of morbidity in cystic fibrosis (CF). Preliminary tients